The Alliance for Clinical Trials in Oncology activated the QUANTUM trial (Alliance A062401) to evaluate a bispecific immunotherapy approach in primary plasma cell leukemia, a rare and aggressive blood cancer. The trial opening marks a focused effort to bring a targeted immunologic strategy into a setting with limited therapeutic options. The QUANTUM activation signals continued expansion of cooperative group infrastructure for rare indications, using standardized protocols to accelerate patient access to investigational therapies. For developers in bispecific immuno-oncology, it also provides a defined pathway for testing novel constructs in an ultra-high-need disease. As the trial enrolls, the key industry watch will be response durability and safety in a population characterized by rapid disease progression and high treatment burden.